On May 16, 2022 Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, reported that it is presenting preclinical proof-of-concept data from its second next-generation SPEAR T-cell (ADP-A2M4N7X19) targeting MAGE-A4, and novel tumor-infiltrating lymphocytes (TILs) expressing IL-7 (ADP-TILIL7) at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) annual meeting (Press release, Adaptimmune, MAY 16, 2022, View Source [SID1234614752]). The Company is presenting the two posters today at 5:30 p.m. EDT during the Cell Therapies I and Targeted Gene and Cell Therapy I sessions.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We have seen impressive clinical results with our first-generation product, afami-cel, in sarcoma, and we set a goal to increase potency to achieve responses in additional indications," said Elliot Norry, Adaptimmune’s Chief Medical Officer. "To that end, we delivered our first next-gen product into the clinic incorporating CD8 and have shown responses across a broad range of solid tumor types in our SURPASS program. We have now presented preclinical data at ASGCT (Free ASGCT Whitepaper) from our second next-gen therapy designed to improve durability and persistence of SPEAR T-cells that supports clinical investigation."
New next-generation SPEAR T-cells show potential for enhanced clinical activity with improved proliferation, survival, and infiltration of immune cells into tumors in preclinical studies
The Company aimed to enhance durability and persistence by engineering a new next-gen SPEAR T-cell targeting MAGE-A4 to secrete IL-7 and CCL19 (ADP-A2M4N7X19) using "Proliferation-Inducing and Migration- Enhancing" (PRIME)1 technology
IL-7 stimulates T-cell proliferation and survival, and CCL19 induces infiltration of immune cells
Naturally occurring T-cells do not express IL-7 or CCL19
Next-generation ADP-A2M4N7X19 SPEAR T-cells were shown to produce IL-7 and CCL19 only in the presence of the MAGE-A4 cancer target
IL-7 production by ADP-A2M4N7X19 SPEAR T-cells enhanced T-cell survival, and CCL19 production induced infiltration of immune cells
Based on these data, Adaptimmune will initiate a Phase 1 clinical trial with ADP-A2M4N7X19 in multiple solid tumor indications
TILs engineered to produce IL-7 may result in a more effective therapy for people with metastatic melanoma with preclinical data demonstrating enhanced TIL survival
TIL therapy has shown some of the most favorable responses in refractory metastatic melanoma2
Adaptimmune applied their lentiviral technology to TILs engineering them to express IL-7 (ADP-TILIL7) with the aim to improve clinical responses
Data indicate that these engineered TILs produce biologically relevant amounts of IL-7; a factor that the TILs cannot produce on their own
IL-7 is known to support T-cell proliferation and survival, which may increase clinical activity and durability of T-cells
Based on these data, a single-center, Phase 1 clinical trial will be initiated at CCIT in Denmark with ADP-TILIL7 to treat patients with metastatic melanoma
The Company will also present a poster entitled "A Novel Flow Cytometry Method for Rapid Assessment of Lentiviral Detection" on May 19th.